- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02076633
Intratumoral Administration of L19IL2/L19TNF
A Phase II Study of Intratumoral Application of L19IL2/L19TNF in Melanoma Patients in Clinical Stage III or Stage IV M1a With Presence of Injectable Cutaneous and/or Subcutaneous Lesions
This Phase II study is an uncontrolled, multicenter, prospective study for patients with malignant melanoma of the skin in clinical stage III or stage IV M1a.
Twenty Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for up to 4 weeks.
The dose will be distributed among the lesions via multiple intralesional injections.
The proportion of patients with complete response at week 12 will be calculated.
Study Overview
Detailed Description
L19IL2 is a recombinant fusion protein composed of a fully human recombinant monoclonal antibody (L19) and the human recombinant interleukin-2 (IL-2).
IL2, is a potent stimulator of the immune response. It has a central role in the regulation of T cell responses and effects on other immune cells such as natural killer cells, B cells, monocyte/macrophages and neutrophils. IL2 can induce tumor regression through its ability to stimulate a potent cell-mediated immune response in vivo.
L19TNF is a recombinant fusion protein composed of a fully human recombinant monoclonal antibody (L19) and the human tumor necrosis factor-alpha, a primary mediator of immune regulation and inflammation.
As an anti-tumor agent, TNF exerts its major effects via a preferential toxicity for the endothelial cells of the tumor-associated vasculature and an increase of the antitumor immune response. Given at sufficient doses (e.g. intratumorally or in the ILP setting with melphalan), TNF causes significant tumor shrinkage in solid cancer subjects.
This phase II signal generating study is designed to test the efficacy and safety of an intratumorally administered mixture of L19IL2 + L19TNF in patients suffering from metastatic melanoma. It is well documented that the intratumoral administration of IL-2 leads to a high response rate and unexpectedly favorable longtime outcome and several tumor responses have been observed in clinical trials of Philogen, both using intratumorally administered L19IL2 and L19TNF in the ILP setting.
Preclinical data produced within the Philogen group now suggest that the intratumoral administration of a mixture of L19IL2 and L19TNF could be even more effective. After only one intratumoral administration of a mixture of L19IL2 and L19TNF tumors disappeared completely while neither L19IL2 nor L19TNF monotherapy was nearly as effective.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Milan, Italy
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Siena, Italy
- Azienda Ospedaliera Universitaria Senese
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed malignant melanoma of the skin in clinical stage III or stage IV M1a
- Presence of measurable and injectable cutaneous and/or subcutaneous lesions
- Males or females, age ≥ 18 years
- ECOG Performance Status/WHO Performance Status ≤ 2
- Life expectancy of at least 12 weeks
- Absolute neutrophil count > 1.5 x 10^9/L
- Hemoglobin > 9.0 g/dL
- Platelets > 100 x 10^9/L
- Total bilirubin ≤ 30 μmol/L (or ≤ 2.0 mg/dl)
- ALT and AST ≤ 2.5 x the upper limit of normal (ULN)
- Serum creatinine < 1.5 x ULN
- LDH serum level within normal range
- All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (v4.02) Grade ≤ 1 unless otherwise specified above
- Negative serum pregnancy test (for women of child-bearing potential only) at screening
- If of childbearing potential, agreement to use adequate contraceptive methods (e.g., oral contraceptives, condoms, or other adequate barrier controls, intrauterine contraceptive devices, or sterilization) beginning at the screening visit and continuing until 3 months following last treatment with study drug.
- Able to provide written Informed Consent
- Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.
Exclusion Criteria:
- Uveal melanoma and mucosal melanoma
- Evidence of visceral metastases and/or active brain metastases at screening
- Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (TA, Tis & Ti) or any cancer curatively treated < 5 years prior to study entry
- History of HIV infection or infectious hepatitis B or C
- Presence of active infections (e.g. requiring antimicrobial therapy) or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
- History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe autoimmune disease
- History of organ allograft or stem cell transplantation
- Recovery from major trauma including surgery within 4 weeks prior to administration of study treatment.
- Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies.
- Breast feeding female
- Anti-tumor therapy within 4 weeks of the administration of study treatment (except small surgery).
- Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before administration of study treatment.
- Planned administration of growth factors or immunomodulatory agents within 7 days before the administration of study treatment
- Patients in need of systemic treatment for rapidly progressive systemic disease.
- Patient requires or is taking corticosteroids or other immunosuppressant drugs on a long-term basis. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions is not considered an exclusion criterion.
- Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: L19IL2 + L19TNF
One arm, intratumoral injections of 10 Mio IU of L19IL2 and 312 μg L19TNF.
Weekly administration for all combined leasions
|
Patients will be treated with intratumoral injections of 10 MioIU L19IL2 and 312μg L19TNF once weekly for up to 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of patients with complete response (CR) of L19IL2 treated Index/Non-Index lesions at week 12.
Time Frame: Week 12
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: 1 year
|
1 year
|
|
Efficacy of L19IL2/L19TNF treated Index/non treated lesions
Time Frame: week 12, 24 and 36
|
|
week 12, 24 and 36
|
Safety of the combination treatment with L19IL2 and L19TNF
Time Frame: 1 year
|
Evaluation of the type and the number of adverse events eventually present
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mario Santinami, Dr, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PH-L19IL2TNF-02/12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Melanoma, Skin
-
National Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant MelanomaUnited States
-
Istituto Scientifico Romagnolo per lo Studio e...UnknownMalignant Melanoma of Skin Stage III | Malignant Melanoma of Skin Stage IVItaly
-
University of ChileCompletedStage III Malignant Melanoma of Skin AJCC V6 | Stage IV Malignant Melanoma of SkinChile
-
National Cancer Institute (NCI)GlaxoSmithKline; Novartis PharmaceuticalsActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...United States
-
National Cancer Institute (NCI)Active, not recruitingMalignant Solid Neoplasm | Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8United States
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenCompletedCutaneous Malignant MelanomaBelgium, Hungary
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of Pennsylvania; RTI International; ITX CorporationCompletedMelanoma and Other Malignant Neoplasms of SkinUnited States
-
M.D. Anderson Cancer CenterMerck Sharp & Dohme LLC; CelgeneActive, not recruitingMetastatic Melanoma | Melanoma and Other Malignant Neoplasms of SkinUnited States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7United States
Clinical Trials on L19IL2+L19TNF
-
Philogen S.p.A.RecruitingMalignant MelanomaItaly, France, Germany, Poland
-
Philogen S.p.A.RecruitingKaposi Sarcoma | Merkel Cell Carcinoma | BCC - Basal Cell Carcinoma | SCC - Squamous Cell Carcinoma | Keratoacanthoma of Skin | Malignant Adnexal Tumors of the Skin (MATS) | Tumors From Cutaneous T-cell Lymphoma (CTCL)Spain, France, Italy
-
Philogen S.p.A.RecruitingCarcinoma, Basal Cell | Carcinoma, Cutaneous Squamous CellGermany, Poland, Switzerland
-
Philogen S.p.A.Merck Sharp & Dohme LLCActive, not recruitingMelanoma Stage IV | Melanoma Stage IIIUnited States
-
Philogen S.p.A.Syneos HealthCompleted
-
Philogen S.p.A.CompletedMalignant MelanomaAustria, Germany
-
Philogen S.p.A.Completed
-
Philogen S.p.A.Active, not recruiting
-
Philogen S.p.A.Eudax S.r.l.TerminatedMetastatic MelanomaSwitzerland, Italy, Austria, Germany
-
Philogen S.p.A.RecruitingGlioblastomaFrance, Germany, Italy, Switzerland